Synageva BioPharma has transferred its headquarters to a larger facility in Lexington, Mass., to provide more space for the development of its experimental drugs for rare diseases. One of the drugs included in the company's pipeline is SBC-102, an enzyme replacement treatment for lysosomal acid lipase deficiency.

Related Summaries